Suramin blocks growth-stimulatory effects of platelet-derived growth factor on malignant fibrous histiocytomas in vitro.
Cancer Lett
; 146(2): 189-94, 1999 Nov 15.
Article
em En
| MEDLINE
| ID: mdl-10656625
ABSTRACT
The pattern of susceptibility of malignant cells to the cytostatic drug suramin is not fully clarified. Therefore, in the present paper we have assessed the effects of suramin on the growth of eight cell lines derived from human malignant fibrous histiocytomas, by measuring DNA synthesis. The effect of suramin (10-200 microg/ml) on cells either unstimulated, or stimulated with platelet-derived growth factor (PDGF)-AA (10 ng/ml), PDGF-BB (10 ng/ml) or 10% fetal calf serum was studied. Four out of five cell lines unable to thrive without external growth factors showed growth inhibition by suramin. The two cell lines able to grow under serum-free conditions were unaffected by high-dose suramin. The exposure to suramin, at 200 microg/ml, abolished the growth stimulation caused by PDGF-AA and -BB. In contrast, a low dose of suramin (50 microg/ml), with or without PDGF, caused growth-stimulating effects in some cell lines. Our results indicate that high doses of suramin inhibit growth of malignant fibrous histiocytomas in vitro and that suramin exerts its growth-inhibitory effects on cells dependent on external growth factors. Low-dose treatment with suramin, however, may instead promote growth in both serum-dependent and -independent tumor cell lines.
Buscar no Google
Bases de dados:
MEDLINE
Assunto principal:
Suramina
/
Fator de Crescimento Derivado de Plaquetas
/
Histiocitoma Fibroso Benigno
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Cancer Lett
Ano de publicação:
1999
Tipo de documento:
Article
País de afiliação:
Suécia